Beta Bionics Faces Class Action Over Alleged iLet Safety Concealment

The legal action, filed by Hagens Berman, covers investors who purchased Beta Bionics common stock between July 30, 2025, and February 24, 2026. Plaintiffs allege that while management marketed the iLet device as requiring minimal user engagement and providing superior automated adaptation, the company simultaneously withheld critical information from the market. Specifically, the complaint asserts that Beta Bionics failed to report thousands of safety incidents, including life-threatening hypoglycemic events, to the Food and Drug Administration.

Tensions peaked following an October 2025 FDA inspection, which resulted in a Form 483. At the time, CEO Sean Saint dismissed the agency’s concerns as a minor procedural issue involving complaint definitions rather than actual device performance. However, a subsequent FDA warning letter issued on January 28, 2026, revealed systemic failures in the company’s quality data analysis and a pattern of neglecting to report device malfunctions linked to serious adverse health outcomes. Hagens Berman partner Reed Kathrein noted the investigation is prioritizing whether the company prioritized revenue over patient safety. Investors seeking to serve as lead plaintiff in the case have until November 3, 2026, to file.